BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS

The invention relates to 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases. 1. (canceled)3. The method of claim 2 , wherein Rand Rare each n-butyl.4. The method of claim 2 , wherein Rand Rare each ethyl.5. The method of claim 2 , wherein Ris n-butyl and Ris ethyl.6. The method of claim 2 , wherein Ris selected from the group consisting of hydrogen claim 2 , bromo claim 2 , hydroxy claim 2 , methoxy claim 2 , amino claim 2 , tert-butoxycarbonylamino claim 2 , methylsulfonamido and cyclopropylsulfonamido.7. The method of claim 2 , wherein Ris selected from the group consisting of hydrogen claim 2 , bromo claim 2 , ethyl claim 2 , cyclopropyl claim 2 , methoxy claim 2 , methylthio and dimethylamino.8. The method of claim 2 , wherein Ris selected from the group consisting of hydrogen and fluoro.9. The method of claim 2 , wherein Ris carboxy.11. The method of claim 2 , wherein the a liver disease or disorder is selected from the group consisting of inherited metabolic disorder of the liver; inborn errors of bile acid synthesis; congenital bile duct anomalies; biliary atresia; neonatal hepatitis; neonatal cholestasis; hereditary forms of cholestasis; cerebrotendinous xanthomatosis; a secondary defect of BA synthesis; Zellweger's syndrome; cystic fibrosis-associated liver disease; alpha1-antitrypsin deficiency; Alagilles syndrome (ALGS); Byler syndrome; a primary defect of bile acid (BA) synthesis; progressive familial intrahepatic cholestasis (PFIC); autoimmune hepatitis; primary biliary cirrhosis (PBC); liver fibrosis; non- ...

Treating Progressive Familial Intrahepatic Cholestasis (PFIC)

Provided herein are methods for treating progressive familial intrahepatic cholestasis (PFIC) with an ileal bile acid transport (IBAT) inhibitor such as odevixibat, or a pharmaceutically acceptable salt thereof. Such methods can include reducing mean pruritus score, mean serum bile acid concentration, increasing height, normalizing weight, improving sleep, and improving liver parameters.

RECONFIGURABLE ANTENNA SYSTEM

A user device selects a communication module from a plurality of communication modules of the user device to communicate first data to a first device in a first configuration, selects a first antenna from a plurality of antennas of the user device to communicate the first data in the first configuration, and couples the communication module to the first antenna in the first configuration. The user device additionally selects the communication module to communicate second data to a second device in a second configuration, selects the first antenna and a second antenna from the plurality of antennas to communicate the second data in the second configuration, and couples the communication module to the first antenna and the second antenna in the second configuration. 1. A method comprising:receiving, by an antenna selector executing on a user device, signal strength data for a connection to a wireless local area network (WLAN) using a first antenna coupled to a WLAN module of the user device, wherein the user device comprises a plurality of wireless modules and a plurality of antennas, the plurality of wireless modules comprising the WLAN module and a wide area network (WAN) module, wherein the WLAN module is configured to output electromagnetic energy in a first frequency band and the WAN module is configured to output electromagnetic energy in a second frequency band;determining, based on the signal strength data, that a signal strength of the connection between the WLAN module and WLAN exceeds a threshold value;determining that a transceiver of the WAN module coupled to a second antenna of the plurality of antennas is idle;determining, by the antenna selector, a first priority for the WAN module and a second priority for the WLAN module, wherein the WLAN module supports multiple-input multiple-output (MIMO), and wherein the second priority is higher than the first priority;causing, by the antenna selector, disconnection of the WAN module from the second antenna; ...

BENZOTHIADIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS

The invention relates to 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases. 1. (canceled)3. The method according to claim 2 , wherein the hyperabsorption syndrome is selected from the group consisting of: abetalipoproteinemia claim 2 , familial hypobetalipoproteinemia (FHBL) claim 2 , chylomicron retention disease (CRD) claim 2 , and sitosterolemia.4. The method according to claim 2 , wherein the disease or disorder is selected from the group consisting of: a cardiovascular disease claim 2 , a disorder of fatty acid metabolism claim 2 , and a glucose utilization disorder.5. The method according to claim 2 , wherein the disease or disorder is a gastrointestinal disease or disorder.6. The method according to claim 4 , wherein the cardiovascular disease or disorder of fatty acid metabolism or glucose utilization disorder is selected from the group consisting of: hypercholesterolemia; disorders of fatty acid metabolism; type 1 and type 2 diabetes mellitus; a complication of diabetes; and a diabetes-related disease.7. The method according to claim 5 , wherein the gastrointestinal disease or disorder is selected from the group consisting of: constipation; Crohn's disease; primary bile acid malabsorption; irritable bowel syndrome (IBS); inflammatory bowel disease (IBD); ileal inflammation; and reflux disease and complications thereof. This application in a continuation of U.S. application Ser. No. 16/805,252, filed Feb. 28, 2020, which is a continuation of International Application No. PCT/EP2020/052942, filed Feb. 6, 2020, which claims priority to ...

Ring-shaped devices with voice integration

Systems, methods, and computer-readable media are disclosed for ring-shaped devices with voice integration. In one embodiment, an example device may include an antenna element that at least partially forms an outer surface of the ring-shaped device, an outer shell coupled to the antenna element, an inner shell coupled to the outer shell, a curved battery disposed along a first side of the ring-shaped device, and a flexible printed circuit assembly coupled to the curved battery and disposed along a second side of the ring shaped device.

Vehicle key activated travel log system

A vehicle key activated travel log system of a vehicle includes a first key with a first key identification code; a second key with a second key identification code different from the first key identification code; and a travel log unit to identify first key and the second key. The system generates a first log book when the first key is identified to start the vehicle.

BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS

The invention relates to 1,5-benzothiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases. 2. A compound according to claim 1 , wherein Ris n-butyl.3. A compound according to claim 1 , wherein Ris n-butyl.4. A compound according to claim 1 , wherein Ris ethyl.5. A compound according to claim 1 , wherein Ris independently selected from the group consisting of hydrogen claim 1 , halogen claim 1 , hydroxy claim 1 , amino claim 1 , cyano claim 1 , Chaloalkyl claim 1 , Calkoxy and Chaloalkoxy.6. A compound according to claim 1 , wherein Ris selected from the group consisting of halogen claim 1 , hydroxy claim 1 , cyano claim 1 , Calkyl claim 1 , Calkoxy claim 1 , Calkylthio claim 1 , amino claim 1 , N—(Calkyl)amino and N claim 1 ,N-di(Calkyl)amino.7. A compound according to claim 1 , wherein Rand Rare each independently selected from the group consisting of hydrogen claim 1 , halogen and hydroxy claim 1 , amino claim 1 , methyl and methoxy.8. A compound according to claim 1 , selected from the group consisting of:(S)-3-((7-bromo-3-butyl-3-ethyl-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)propanoic acid;(R)-3-((7-bromo-3-butyl-3-ethyl-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)propanoic acid;3-((7-bromo-3,3-dibutyl-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)propanoic acid;3-((3-butyl-7-chloro-3-ethyl-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)propanoic acid;(S)-3-((3-butyl-7-chloro-3-ethyl-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)propanoic acid ...

BENZOTHIADIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS

The invention relates to 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases. 2. A compound according to claim 1 , wherein Ris n-butyl.3. A compound according to claim 1 , wherein Ris n-butyl.4. A compound according to claim 1 , wherein Ris ethyl.5. A compound according claim 1 , wherein Ris independently selected from the group consisting of hydrogen claim 1 , halogen claim 1 , hydroxy claim 1 , amino claim 1 , cyano claim 1 , Chaloalkyl claim 1 , Calkoxy and Chaloalkoxy.6. A compound according to claim 1 , wherein Ris selected from the group consisting of halogen claim 1 , hydroxy claim 1 , cyano claim 1 , Calkyl claim 1 , Calkoxy claim 1 , Calkylthio claim 1 , amino claim 1 , N—(Calkyl)amino and N claim 1 ,N-di(Calkyl)amino.7. A compound according to claim 1 , wherein Rand Rare each independently selected from the group consisting of hydrogen claim 1 , halogen claim 1 , hydroxy claim 1 , amino and methyl.8. A compound according to claim 1 , wherein Ris hydrogen or methyl.10. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1 , and one or more pharmaceutically acceptable excipients.11. (canceled)12. The method according to claim 17 , wherein the cardiovascular disease or disorder of fatty acid metabolism or glucose utilization disorder is selected from the group consisting of: hypercholesterolemia; a disorder of fatty acid metabolism; type 1 and type 2 diabetes mellitus; and a complication of diabetes.13. The method according to claim 18 , wherein the gastrointestinal disease or ...

BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS

The invention relates to 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases. 2. A compound according to claim 1 , wherein Rand Rare each n-butyl.3. A compound according to claim 1 , wherein Rand Rare each ethyl.4. A compound according to claim 1 , wherein Ris n-butyl and Ris ethyl.5. A compound according to claim 1 , wherein Ris selected from the group consisting of hydrogen claim 1 , bromo claim 1 , hydroxy claim 1 , methoxy claim 1 , amino claim 1 , tert-butoxycarbonylamino claim 1 , methylsulfonamido and cyclopropylsulfonamido.6. A compound claim 1 , wherein Ris selected from the group consisting of hydrogen claim 1 , bromo claim 1 , ethyl claim 1 , cyclopropyl claim 1 , methoxy claim 1 , methylthio and dimethylamino.7. A compound according to claim 1 , wherein Ris selected from the group consisting of hydrogen and fluoro.8. A compound according to claim 1 , wherein Ris carboxy.10. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , and one or more pharmaceutically acceptable excipients.1115.-. (canceled)16. A method for treating a cardiovascular disease claim 1 , a disorder of fatty acid metabolism claim 1 , a glucose utilization disorder claim 1 , or a gastrointestinal disease or disorder comprising orally administering to a subject in need of such treatment a therapeutically effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof.17. The method of claim 16 , ...

Tunable monopole antenna with unified grounding structure

The disclosed system may include an enclosure that is configured to house a printed circuit board (PCB). The PCB may have various internal electrical components mounted thereto. The system may also include a radiating component mounted to an opposite side of the PCB. Still further, the system may include a unified grounding structure that couples the PCB to the enclosure in multiple locations. As such, the radiating component may be grounded to the unified grounding structure at the multiple different locations. Various other methods, systems, and computer-readable media are also disclosed, including methods of manufacturing mobile electronic devices.

Benzothiazepine compounds and their use as bile acid modulators

The invention relates to 1,5-benzothiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium- dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.

Use of mglur5 antagonists for the treatment of gerd

Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd)

The present invention relates to the use of a compound of formula (II) for the inhibition of transient lower esophageal sphincter relaxations. A further aspect of the invention is directed to the use of compounds of formula (II) for the treatment of gastro-esophageal reflux disease.

Imidazole variants as modulators of GABA receptor for the treatment of GI disorders

Disclosed is a compound of formula (I), wherein the substituents are as disclosed therein. Also disclosed is the use of the compound as a GABA(B) receptor modulator, and for treating gastroesophageal reflux disease (GERD), reflux, transient lower esophageal sphincter relaxations (TLESRs), a gastrointestinal disorder such as functional dyspepsia, or irritable bowel syndrome. Also disclosed is a process for preparing the compounds, and intermediates for that process.

Imidazole variants as modulators of GABA receptor for the treatment of gastrointestinal disorders

USE OF MGLUR5 ANTAGONISTS FOR THE TREATMENT OF GASTROESOPHAGAL REFLUXES

Ring-shaped electronic device

Heparin derivatives for treatment of angina pectoris

The invention relates to new heparin derivatives from bovine or porcine heparin which have a molecular weight equal to or larger than the standard heparin, show a sulfur content which is equal to or higher than that of the starting heparin or at least 13% w/w, have an anticoagulant activity in the anti-FXa assay of less than 10% of the standard heparin it was made from , show a ratio of APTT activity over anti-FXa activity of 3-35, show a reduced prolongation of bleeding time compared to the standard heparin it was made from as measured in the rat tail after i.v. administration and show enhancement of the rate of development of coronary collaterals in dogs equal to or better than clinically used heparin. The invention also relates to processes for preparation of the new bovine and porcine heparin derivatives. The use of this product for the manufacturing of a medicament for treatment of ischemic heart disease and related vascular disorders and for the enhancement of the rate of development of coronary collateral perfusion is disclosed.

Adaptive antenna tuning based on a sensed characteristic

A user device obtains sensor data from sensors included in the user device. A set of current state information is determined based on the sensor data. A tuner code associated with the current state information is identified. Tuning values associated with the tuner code are varied during a training stage to determine an optimized tuner code. One or more antennae of the user device are tuned for communication in accordance with the optimized tuner code.

Benzothia(di)azepine compounds and their use as bile acid modulators

The invention relates to1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.

PIFA antenna with extendable part

Oligosaccharide-containing inhibitors of endothelial cell growth and angiogenesis

ABSTRACT OF THE DISCLOSURE Novel fractions comprising oligosaccharides having 6 to 8 saccharide units and molecular weights between 1,000 and 2,000 and a sulfur content of less than 9 weight percent, are obtained by depolymerizing heparin or heparan sulfate and fractionating the digest by size and charge. These fractions inhibit capillary endothelial cell proliferation in Vitro and are useful in the in vivo inhibition of angiogenesis.

Treatment of reflux-related diseases

The present invention relates to the use of certain compounds for the inhibition of transient lower esophageal sphincter relaxations. A further aspect of the invention is directed to the use of certain compounds for the treatment of gastro-esophageal reflux disease, regurgitation, asthma, laryngitis, lung disease and for managing failure.

Endothelial multiplication of cells and the olygosaccharide containing inhibitors of angiogenesis

Treatment of gastro-esophageal reflux disease (gerd)

The present invention relates to the use of a compound of formula (I) for the inhibition of transient lower esophageal sphincter relaxations. A further aspect of the invention is directed to the use of compounds of formula (I) for the treatment of gastro-esophageal reflux disease.

Benzothiadiazepine compounds and their use as bile acid modulators

Imidazole variants as modulators of gaba receptor for the treatment of gi disorders

Box No. IV Text of the abstract (Continuation of item 5 of the first sheet) The present invention relates to novel compounds having a positive allosteric GÀBAB receptor (GDR) modulator effect, methods for the preparation of said compounds and to their use, optionally in combination with a GABAB agonist, for the inhibition of transient lower esophageal sphincter relaxations, for the treatment of gastroesophageal reflux disease, as well as for the treatment of functional gastrointestinal disorders and irritable bowel syndrome (IBS). A compound of the general formula I

Use of mglur5 antagonists for the treatment of gerd

The present invention relates to the use of metabotropic glutamate receptor 5 antagonists for the inhibition of transient lower esophageal sphincter relaxations. A further aspects of the invention is directed to the use of metabotropic glutamate receptor 5 antagonists for the treatment of gastro, esophageal reflux disease, as well as for the treatment of regurgitation and asthma.

Benzothiadiazepine compounds and their use as bile acid modulators

The invention relates to 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.

Treatment of gastro-esophageal reflux disease (gerd)

The present invention relates to the use of a compound of formula (I) for the inhibition of transient lower esophageal sphincter relaxations. A further aspect of the invention is directed to the use of compounds of formula (I) for the treatment of gastro-esophageal reflux disease.

Treating hepatitis

Provided herein are methods for treating hepatitis B and/or D with an Na+/taurocholate co-transporting polypeptide (NTCP) inhibitor such as a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a compound of formula (II), or a pharmaceutically acceptable salt thereof. Such methods can include decreasing the concentration of hepatitis B DNA, decreasing the concentration of hepatitis D DNA, decreasing hepatitis B surface antigen, and decreasing hepatitis B core antigen (HBcAg).

Compuestos de benzotiazepina y su uso como moduladores de los ácidos biliares

La invención se refiere a derivados de 1,5-benzotiazepina de fórmula (I). Estos compuestos son moduladores de ácidos biliares que tienen actividad inhibidora del transportador apical de ácidos biliares dependiente de sodio (ASBT) y/o del transporte hepático de ácidos biliares (LBAT). La invención también se refiere a composiciones farmacéuticas que comprenden estos compuestos y al uso de estos compuestos en el tratamiento de enfermedades cardiovasculares, trastornos del metabolismo de los ácidos grasos y de la utilización de la glucosa, enfermedades gastrointestinales y enfermedades hepáticas. (Traducción automática con Google Translate, sin valor legal)

Treating hepatitis

Provided herein are methods for treating hepatitis B and/or D with an Na+/taurocholate co-transporting polypeptide (NTCP) inhibitor such as a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a compound of formula (II), or a pharmaceutically acceptable salt thereof. Such methods can include decreasing the concentration of hepatitis B DNA, decreasing the concentration of hepatitis D DNA, decreasing hepatitis B surface antigen, and decreasing hepatitis B core antigen (HBcAg).

Antenna architecture for a wearable device and related devices and methods

The disclosed mobile electronic device may include a display, an enclosure supporting the display and comprising a conductive portion, a ground plane positioned within the enclosure, wherein a gap defined between the conductive portion of the enclosure and the ground plane forms a slot antenna that is configured to radiate first electromagnetic signals through a portion of the display, the first electromagnetic signals radiated by the slot antenna being used for wireless communication in a first wireless communication band, and a patch antenna, comprising a substantially planar conductor, that is configured to radiate second electromagnetic signals, the second electromagnetic signals radiated by the patch antenna being used for wireless communication in a second wireless communication band different from the first wireless communication band. Various other related methods and systems are also disclosed.

Verwendung von mglur5 antagonisten zur behandlung von gastroesophagalen refluxen

Subcutaneous administration of an asbt inhibitor

The invention relates to an apical sodium-dependent bile acid transporter (ASBT) inhibitor for use in the treatment of a liver or renal disease or disorder, wherein the ASBT inhibitor is administered subcutaneously. Such administration also targets the ASBT in the kidneys and may therefore be useful in the treatment of liver or renal diseases and conditions requiring a stronger inhibition of bile acid circulation, such as in the treatment of cholestatic liver diseases and conditions comprising biliary obstruction or an impaired or defective biliary flow.

Ring-shaped devices with voice integration

Systems, methods, and computer-readable media are disclosed for ring-shaped devices with voice integration. In one embodiment, an example device may include an antenna element that at least partially forms an outer surface of the ring-shaped device, an outer shell coupled to the antenna element, an inner shell coupled to the outer shell, a curved battery disposed along a first side of the ring-shaped device, and a flexible printed circuit assembly coupled to the curved battery and disposed along a second side of the ring shaped device.

Individual radio frequency configuration for user devices

Systems, devices, methods, computer-readable media, techniques, and methodologies are disclosed for optimizing radio frequency configuration of a user device for better power management and faster time to first fix. The radio frequency configuration of user devices may be optimized based on user input analysis, machine learning, or crowd sourcing methodologies.

Compuestos de benzotiazepina y su uso como moduladores de ácido biliar

La presente se refiere a derivados de 1,5-benzotiazepina de fórmula (1). Estos compuestos son moduladores de los ácidos biliares que tienen una actividad inhibidora en el transportador apical de ácidos biliares que dependen de sodio (ASBT) y/o en el transporte de ácidos biliares del hígado (LBAT). La presente también se refiere a composiciones farmacéuticas que comprenden estos compuestos y al uso de estos compuestos en el tratamiento de enfermedades cardiovasculares, metabolismo de ácidos grasos y trastornos de utilización de glucosa, enfermedades gastrointestinales y enfermedades hepáticas. Reivindicación 1: Un compuesto de la fórmula (1) caracterizado porque R¹ y R² cada uno de manera independiente alquilo C₁₋₄; R³ se selecciona de manera independiente del grupo que consiste en hidrógeno, halógeno, hidroxi, alquilo C₁₋₄, haloalquilo C₁₋₄, alcoxi C₁₋₄, haloalcoxi C₁₋₄, ciano, nitro, amino, N-(alquilo C₁₋₄)amino, N,N-di(alquilo C₁₋₄)amino y N-(aril-alquilo C₁₋₄)amino; n es un número entero 1, 2 ó 3; R⁴ se selecciona del grupo que consiste en hidrógeno, halógeno, hidroxi, ciano y alquilo C₁₋₄, cicloalquilo C₃₋₆, alcoxi C₁₋₄, cicloalquiloxi C₃₋₆, alquiltio C₁₋₄, cicloalquiltio C₃₋₆, amino, N-(alquilo C₁₋₄)amino y N,N-di(alquilo C₁₋₄)amino; y R⁵A, R⁵B, R⁵C y R⁵D se seleccionan independientemente del grupo que consiste en hidrógeno, halógeno, hidroxi, amino, alquilo C₁₋₄ y alcoxi C₁₋₄; o una sal farmacéuticamente aceptable de este; con la condición de que el compuesto no sea ácido 3-((7-bromo-3-butil-3-etil-1,1-dioxido-5-fenil-2,3,4,5-tetrahidro-1,5-benzotiazepina-8-il)oxi)propanoico racémico.

Subcutaneous administration of an asbt inhibitor

The invention relates to an apical sodium-dependent bile acid transporter (ASBT) inhibitor for use in the treatment of a liver or renal disease or disorder, wherein the ASBT inhibitor is administered subcutaneously. Such administration also targets the ASBT in the kidneys and may therefore be useful in the treatment of liver or renal diseases and conditions requiring a stronger inhibition of bile acid circulation, such as in the treatment of cholestatic liver diseases and conditions comprising biliary obstruction or an impaired or defective biliary flow.

Ring-shaped devices with voice integration

Systems, methods, and computer-readable media are disclosed for ring-shaped devices with voice integration. In one embodiment, an example device may include an antenna element that at least partially forms an outer surface of the ring-shaped device, an outer shell coupled to the antenna element, an inner shell coupled to the outer shell, a curved battery disposed along a first side of the ring-shaped device, and a flexible printed circuit assembly coupled to the curved battery and disposed along a second side of the ring shaped device.

Ringförmige Vorrichtungen mit Sprachintegration

Systeme, Verfahren und computerlesbare Medien für ringförmige Vorrichtungen mit Sprachintegration werden offenbart. In einer Ausführungsform kann eine beispielhafte Vorrichtung ein Antennenelement, das zumindest teilweise eine Außenfläche der ringförmigen Vorrichtung bildet, eine mit dem Antennenelement gekoppelte Außenschale, eine mit der Außenschale verbundene Innenschale, eine gebogene Batterie, die entlang einer ersten Seite der ringförmigen Vorrichtung angeordnet ist, und eine flexible Platinenbaugruppe, die mit der gebogenen Batterie verbunden und entlang einer zweiten Seite der ringförmigen Vorrichtung angeordnet ist, umfassen.

Elevated feed antenna for wearable electronic devices

The disclosed system may include a housing that includes a non-conducting substrate and a conductive enclosure that at least partially surrounds the non-conducting substrate. The system may also include an antenna disposed on the non-conducting substrate of the housing. Still further, the system may include a direct electrical connection between the antenna and a first portion of the conductive enclosure. Moreover, the system may include an antenna feed electrically connected to a separate conductive portion on the non-conducting substrate. The separate portion of the non-conducting substrate may be electrically connected to a second portion of the conductive enclosure. Various other apparatuses, wearable electronic devices, and methods of manufacturing are also disclosed.

Treating Progressive Familial Intrahepatic Cholestasis (PFIC) with IBAT Inhibitors

Provided herein are methods for treating progressive familial intrahepatic cholestasis (PFIC) with an ileal bile acid transport (IBAT) inhibitor such as odevixibat, or a pharmaceutically acceptable salt thereof. Such methods can include reducing mean pruritus score, mean serum bile acid concentration, increasing height, normalizing weight, improving sleep, and improving liver parameters.

Treating alagille syndrome (algs)

Provided herein are methods for Alagille syndrome (ALGS) with an ileal bile acid transport (IBAT) inhibitor such as odevixibat, or a pharmaceutically acceptable salt thereof. Such methods can include reducing pruritus score, serum bile acid concentration, increasing height, normalizing weight, improving sleep, and improving liver parameters.

Benzothiazepine compounds and their use as bile acid modulators

The invention relates to 1,5-benzothiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.

Context-aware antenna tuning

The disclosed computer-implemented method may include accessing various portions of contextual information based on at least one touch input from a touch-based sensor on a mobile electronic device. The method may next include determining, based on the contextual information, which of different operational antenna parameters associated with at least one antenna of the mobile electronic device are to be changed. The method may then include changing the specified operational parameters associated with the antenna on the mobile electronic device according to the determination. Various other methods, systems, and computer-readable media are also disclosed.

Festelement

Wireless communication device with strategically positioned antenna

A wireless communication device (200) is provided, the wireless communication device (200) can include at least one antenna (240), the antenna (240) positioned beneath the face plate (252) and base plate (255) of a user interface (245) of the wireless communication device (200) in which the antenna (240) can be configured to communicate with a signal source.

Benzothiadiazepine compounds and their use as bile acid modulators

The invention relates to 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.

Treating Alagille Syndrome (ALGS)

Provided herein are methods for Alagille syndrome (ALGS) with an ileal bile acid transport (IBAT) inhibitor such as odevixibat, or a pharmaceutically acceptable salt thereof. Such methods can include reducing pruritus score, serum bile acid concentration, increasing height, normalizing weight, improving sleep, and improving liver parameters.

Compuestos de benzotiadiazepina y su uso como moduladores de ácido biliar

La presente se refiere a derivados de 1,2,5-benzotiadiazepina de fórmula (1). Estos compuestos son moduladores de los ácidos biliares que tienen una actividad inhibidora en el transportador apical de ácidos biliares que dependen de sodio (ASBT) y/o en el transporte de ácidos biliares del hígado (LBAT). La presente también se refiere a composiciones farmacéuticas que comprenden estos compuestos y al uso de estos compuestos en el tratamiento de enfermedades cardiovasculares, metabolismo de ácidos grasos y trastornos de utilización de glucosa, enfermedades gastrointestinales y enfermedades hepáticas. Reivindicación 1: Un compuesto de la fórmula (1) donde R¹ y R² cada uno de manera independiente alquilo C₁₋₄; R³ se selecciona de manera independiente del grupo que consiste en hidrógeno, halógeno, hidroxi, alquilo C₁₋₄, haloalquilo C₁₋₄, alcoxi C₁₋₄, haloalcoxi C₁₋₄, ciano, nitro, amino, amino N-(alquilo C₁₋₄), amino N,N-di(alquilo C₁₋₄) y amino N-(aril-alquilo C₁₋₄); n es un número entero 1, 2 ó 3; R⁴ se selecciona del grupo que consiste en hidrógeno, halógeno, hidroxi, ciano, alquilo C₁₋₄, cicloalquilo C₃₋₆, alcoxi C₁₋₄, cicloalquiloxi C₃₋₆, alquilotio C₁₋₄, cicloalquilotio C₃₋₆, amino, amino N-(alquilo C₁₋₄) y amino N,N-di(alquilo C₁₋₄); R⁵A, R⁵B, R⁵C y R⁵D cada uno se selecciona de manera independiente del grupo que consiste en hidrógeno, halógeno, hidroxi, amino y alquilo C₁₋₄; y R⁶ se selecciona del grupo que consiste en hidrógeno y alquilo C₁₋₄; o una sal farmacéuticamente aceptable de este.

Kantmarkering vid vägräcken

Wireless communication device with strategically positioned antenna

A wireless communication device (200) is provided, the wireless communication device (200) can include at least one antenna (240), the antenna (240) positioned beneath the face plate (252) and base plate (255) of a user interface (245) of the wireless communication device (200) in which the antenna (240) can be configured to communicate with a signal source.

Systems and methods for antenna design

The disclosed computer-implemented method may include generating, using a machine-learning model of a computing device, a set of antenna designs. The method may also include tokenizing, by the computing device, each antenna design in the generated set of antenna designs. Additionally, the method may include predicting, by the machine-learning model of the computing device, a frequency response for each tokenized antenna design. Furthermore, the method may include comparing, by the computing device, the frequency response for each tokenized antenna design. Finally, the method may include selecting, by the computing device based on the comparison, an antenna design that meets a performance threshold for the frequency response. Various other methods, systems, and computer-readable media are also disclosed.

Anordning ved stolpe med skilt

Wireless communication device with strategically positioned antenna

A wireless communication device (200) is provided, the wireless communication device (200) can include at least one antenna (240), the antenna (240) positioned beneath the face plate (252) and base plate (255) of a user interface (245) of the wireless communication device (200) in which the antenna (240) can be configured to communicate with a signal source.

Wireless communication device with strategically positioned antenna

Electronic device charger

Systems and methods for artificial intelligence assisted antenna design

A disclosed computer-implemented method may include (1) receiving (A) a set of design specifications associated with an antenna performance characteristic, (B) a set of requirements for an antenna architecture, (C) a parameterization that describes parameters of an antenna structure, and (D) a set of bounds for the parameterization, and (2) determining, based on the set of design specifications, the set of requirements, the parameterization, and the set of bounds, and in accordance with a global optimization algorithm and a local tuning algorithm, a design for the antenna architecture. Various other methods, systems, and computer-readable media are also disclosed.

Antenna system for wearable devices

The disclosed system may include an enclosure that is configured to house internal electrical components disposed on a printed circuit board (PCB). The system may also include a first antenna feed that is electrically connected to the PCB, to the enclosure, and to a radiating coupling arm configured for wireless communication in a first wireless communication band. The system may further include a second antenna feed that is electrically connected to the PCB and to an antenna configured for wireless communication in a second, different wireless communication band. The system may also include a first grounding leg that forms an electrical ground between the PCB and the enclosure, and a second, switchable grounding leg positioned away from the first grounding leg. This switchable grounding leg may provide a controllable electrical ground between the PCB and the enclosure. Various other methods and apparatuses are also disclosed.

Sammankopplingselement för att fast förbinda två korsande långsträckta kroppar med varandra

Antenna design using artificial intelligence

The disclosed computer-implemented method may include accessing various antenna elements (210) and identifying parameters for an antenna that is to be formed using the accessed antenna elements (220). The method may also include assembling the antenna elements (230), using an artificial intelligence (AI) instance, into an assembled antenna that at least partially complies with the identified parameters. Various other methods, systems, and computer-readable media are also disclosed.

Kilvellä varustetun pylvään järjestely

Anordning vid stolpe med skylt

Kilvellä varustetun pylvään järjestely

Benzothiazepine compounds and their use as bile acid modulators

The invention relates to 1,5-benzothiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.

Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)

Provided herein are methods for treating progressive familial intrahepatic cholestasis (PFIC) with an ileal bile acid transport (IBAT) inhibitor such as odevixibat, or a pharmaceutically acceptable salt thereof. Such methods can include reducing mean pruritus score, mean serum bile acid concentration, increasing height, normalizing weight, improving sleep, and improving liver parameters.

Benzothiadiazepine compounds and their use as bile acid modulators

The invention relates to 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.

Benzothiadiazepine compounds and their use as bile acid modulators

Benzotiadiazepinski spojevi i njihova uporaba kao modulatora žučnih kiselina

Compuestos de benzotiadiazepina y su uso como moduladores del ácido biliar

[00769] La invención se refiere a los derivados 1,2,5 de benzotiadiazepina de la fórmula (I). Estos compuestos son moduladores del ácido biliar que tienen el transportador apical del ácido biliar dependiente del sodio (ASBT) y/o actividad inhibidora del transporte del ácido biliar del hígado (LBAT). La invención también se refiere a las composiciones farmacéuticas que comprenden estos compuestos y con el uso de estos compuestos en el tratamiento de enfermedades cardiovasculares, metabolismo del ácido graso y trastornos debido al uso de la glucosa, enfermedades gastrointestinales y enfermedades hepáticas.

Reflexbärare vid vägräcken

Benzotiadiazepinska jedinjenja i njihova upotreba kao modulatora žučnih kiselina

Antenna system for wearable devices

The disclosed system may include an enclosure that is configured to house internal electrical components disposed on a printed circuit board (PCB). The system may also include a first antenna feed that is electrically connected to the PCB, to the enclosure, and to a radiating coupling arm configured for wireless communication in a first wireless communication band. The system may further include a second antenna feed that is electrically connected to the PCB and to an antenna configured for wireless communication in a second, different wireless communication band. The system may also include a first grounding leg that forms an electrical ground between the PCB and the enclosure, and a second, switchable grounding leg positioned away from the first grounding leg. This switchable grounding leg may provide a controllable electrical ground between the PCB and the enclosure. Various other methods and apparatuses are also disclosed.

Antenna architecture for a wearable device and related devices and methods

The disclosed mobile electronic device may include a display, an enclosure supporting the display and comprising a conductive portion, a ground plane positioned within the enclosure, wherein a gap defined between the conductive portion of the enclosure and the ground plane forms a slot antenna that is configured to radiate first electromagnetic signals through a portion of the display, the first electromagnetic signals radiated by the slot antenna being used for wireless communication in a first wireless communication band, and a patch antenna, comprising a substantially planar conductor, that is configured to radiate second electromagnetic signals, the second electromagnetic signals radiated by the patch antenna being used for wireless communication in a second wireless communication band different from the first wireless communication band. Various other related methods and systems are also disclosed.

Antenna design using artificial intelligence

The disclosed computer-implemented method may include accessing various antenna elements and identifying parameters for an antenna that is to be formed using the accessed antenna elements. The method may also include assembling the antenna elements, using an artificial intelligence (AI) instance, into an assembled antenna that at least partially complies with the identified parameters. Various other methods, systems, and computer-readable media are also disclosed.

Antenna design using artificial intelligence

The disclosed computer-implemented method may include accessing various antenna elements and identifying parameters for an antenna that is to be formed using the accessed antenna elements. The method may also include assembling the antenna elements, using an artificial intelligence (AI) instance, into an assembled antenna that at least partially complies with the identified parameters. Various other methods, systems, and computer-readable media are also disclosed.

Bowtie monopole antenna and communication device using same

A bowtie monopole antenna is fabricated of a sheet metal radiating body 102 that is triangular shaped, and having a longitudinal dimension and axis (106) and a width (108). One corner of the radiating body is tapered to form a feed point (104). The length dimension determines the antenna's lowest resonance frequency while the taper created by the width determines the highest point of resonance. For using the bowtie monopole antenna in a communication device, the radiating body (102) is folded or wrapped around towards itself. To facilitate the folding or wrapping a mounting substrate (202) is used. The substrate may be provided with retaining features (206) to capture the antenna assembly within the communication device.

Ventilerat golv

Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)

Provided herein are methods for treating progressive familial intrahepatic cholestasis (PFIC) with an ileal bile acid transport (IBAT) inhibitor such as odevixibat, or a pharmaceutically acceptable salt thereof. Such methods can include reducing mean pruritus score, mean serum bile acid concentration, increasing height, normalizing weight, improving sleep, and improving liver parameters.

Context-aware antenna tuning

The disclosed computer-implemented method may include accessing various portions of contextual information based on at least one touch input from a touch-based sensor on a mobile electronic device. The method may next include determining, based on the contextual information, which of different operational antenna parameters associated with at least one antenna of the mobile electronic device are to be changed. The method may then include changing the specified operational parameters associated with the antenna on the mobile electronic device according to the determination. Various other methods, systems, and computer-readable media are also disclosed.

Anordning vid golv

Subcutaneous administration of an asbt inhibitor

The invention relates to an apical sodium-dependent bile acid transporter (ASBT) inhibitor for use in the treatment of a liver or renal disease or disorder, wherein the ASBT inhibitor is administered subcutaneously. Such administration also targets the ASBT in the kidneys and may therefore be useful in the treatment of liver or renal diseases and conditions requiring a stronger inhibition of bile acid circulation, such as in the treatment of cholestatic liver diseases and conditions comprising biliary obstruction or an impaired or defective biliary flow.

Antenna carriers with magneto-dielectric material and beam-shaping elements for enhanced performance and radiation safety of electronic devices

Antenna carriers with magneto-dielectric material and beam-shaping elements for enhanced performance and radiation safety of electronic devices are described. One electronic device includes a housing, an antenna element disposed on an antenna carrier, and a printed circuit board (PCB) disposed within the housing, the printed circuit board including radio frequency (RF) circuitry. The antenna carrier can be made up of a plastic cap, a ground plane, and a magneto-dielectric substrate with both dielectric and magnetic properties. The plastic cap is disposed at a first side of the housing and the magneto-dielectric substrate is disposed on a top surface of the plastic cap. The antenna element is disposed on a bottom surface of the magneto-dielectric substrate and electrically coupled to the RF circuitry. The antenna element radiates electromagnetic energy in a resonant mode and the magnetic property of the magneto-dielectric material increase efficiency, frequency bandwidth, or both.

Reconfigurable antenna system

A user device selects a communication module from a plurality of communication modules of the user device to communicate first data to a first device in a first configuration, selects a first antenna from a plurality of antennas of the user device to communicate the first data in the first configuration, and couples the communication module to the first antenna in the first configuration. The user device additionally selects the communication module to communicate second data to a second device in a second configuration, selects the first antenna and a second antenna from the plurality of antennas to communicate the second data in the second configuration, and couples the communication module to the first antenna and the second antenna in the second configuration.

Split band antenna design

Antenna structures and methods of operating the same of an electronic device are described. One apparatus includes a single radio frequency (RF) feed and a folded monopole element coupled to the single RF feed. The folded monopole element is an integrated WAN/GNSS antenna that receives electromagnetic energy in a first frequency band and receives electromagnetic energy in a second frequency band. The first frequency band is a wireless area network (WAN) frequency band and the second frequency band is a global navigation satellite system (GNSS) frequency band. The apparatus further includes an impedance matching circuit coupled to the single RF feed. The impedance matching circuit includes a diplexer to extract out GNSS frequency signals received by the folded monopole element from WAN signals received by the folded monopole element.

Mobile antenna array

A plurality of UAVs may be operated in a fleet, each of the UAVs in the fleet being configured to work collectively to achieve one or more functions, such as to create a display or implement an antenna array. The fleet of UAVs may operate individually and/or may be coupled to one another to operate as a collective unit. In some embodiments, one or more UAVs in the fleet may operate individually, while two or more UAVs in the fleet may be connected to one another. In such embodiments, the individual UAVs and the connected UAVs may together comprise the fleet.